Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure

被引:3
作者
Tang, Amber B. [1 ]
Ziaeian, Boback [2 ]
Butler, Javed [3 ,4 ]
Yancy, Clyde W. [5 ]
Fonarow, Gregg C. [2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Div Cardiol, 10833 LeConte Ave, Los Angeles, CA 90095 USA
[3] Baylor Scott & White Res Inst, Dallas, TX USA
[4] Univ Mississippi, Jackson, MS USA
[5] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA
关键词
D O I
10.1001/jamacardio.2024.3023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ImportanceGuideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated. ObjectiveTo assess the projected population-level benefit of optimal GDMT use globally among patients with HFrEF. Design, Setting, and ParticipantsEstimates for HFrEF prevalence, contraindications to GDMT, treatment rates, and the number needed to treat for all-cause mortality at 12 months were derived from previously published sources. Potential lives saved from optimal implementation of quadruple therapy among patients with HFrEF was calculated globally and a sensitivity analysis was conducted to account for uncertainty in the existing data. Main Outcomes and MeasuresAll-cause mortality. ResultsOf an estimated 28.89 million people with HFrEF worldwide, there were 8 235 063 (95% CI, 6 296 020-10 762 972) potentially eligible for but not receiving beta-blockers, 20 387 000 (95% CI, 15 867 004-26 184 996) eligible for but not receiving angiotensin receptor-neprilysin inhibitors, 12 223 700 (95% CI, 9 376 895-15 924 973) eligible for but not receiving mineralocorticoid receptor antagonists, and 21 229 170 (95% CI, 16 537 400-27 242 688) eligible for but not receiving sodium glucose cotransporter-2 inhibitors. Optimal implementation of quadruple GDMT could potentially prevent 1 188 277 (95% CI, 767 933-1 914 561) deaths over 12 months. A large proportion of deaths averted were projected in Southeast Asia, Eastern Mediterranean and Africa, and the Western Pacific regions. Conclusions and RelevanceImprovement in use of GDMT could result in substantial mortality benefits on a global scale. Significant heterogeneity also exists across regions, which warrants additional study with interventions tailored to country-level differences for optimization of GDMT worldwide.
引用
收藏
页码:1154 / 1158
页数:5
相关论文
共 14 条
[1]   An overview of heart failure in low- and middle-income countries [J].
Agbor, Valirie N. ;
Ntusi, Ntobeko A. B. ;
Noubiap, Jean Jacques .
CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2020, 10 (02) :244-251
[2]   Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure [J].
Bassi, Nikhil S. ;
Ziaeian, Boback ;
Yancy, Clyde W. ;
Fonarow, Gregg C. .
JAMA CARDIOLOGY, 2020, 5 (08) :948-951
[3]   Potential survival gains in the treatment of myocardial infarction [J].
Chew, D. P. ;
Huynh, L. T. ;
Liew, D. ;
Astley, C. ;
Soman, A. ;
Brieger, D. .
HEART, 2009, 95 (22) :1844-1850
[4]   Potential impact of optimal implementation of evidence-based heart failure therapies on mortality [J].
Fonarow, Gregg C. ;
Yancy, Clyde W. ;
Hernandez, Adrian F. ;
Peterson, Eric D. ;
Spertus, John A. ;
Heidenreich, Paul A. .
AMERICAN HEART JOURNAL, 2011, 161 (06) :1024-U244
[5]   Eligibility and Projected Benefits fi ts of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure [J].
Greene, Stephen J. ;
Ayodele, Iyanuoluwa ;
Pierce, Jacob B. ;
Khan, Muhammad Shahzeb ;
Lewsey, Sabra C. ;
Yancy, Clyde W. ;
Alhanti, Brooke ;
Van Spall, Harriette G. C. ;
Allen, Larry A. ;
Fonarow, Gregg C. .
JACC-HEART FAILURE, 2024, 12 (08) :1365-1377
[6]   2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [J].
Heidenreich, Paul A. ;
Bozkurt, Biykem ;
Aguilar, David ;
Allen, Larry A. ;
Byun, Joni J. ;
Colvin, Monica M. ;
Deswal, Anita ;
Drazner, Mark H. ;
Dunlay, Shannon M. ;
Evers, Linda R. ;
Fang, James C. ;
Fedson, Savitri E. ;
Fonarow, Gregg C. ;
Hayek, Salim S. ;
Hernandez, Adrian F. ;
Khazanie, Prateeti ;
Kittleson, Michelle M. ;
Lee, Christopher S. ;
Link, Mark S. ;
Milano, Carmelo A. ;
Nnacheta, Lorraine C. ;
Sandhu, Alexander T. ;
Stevenson, Lynne Warner ;
Vardeny, Orly ;
Vest, Amanda R. ;
Yancy, Clyde W. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (17) :E253-E421
[7]   Preventing Stroke in Patients With Atrial Fibrillation- A Steep Climb Away From Achieving Peak Performance [J].
Piccini, Jonathan P. ;
Fonarow, Gregg C. .
JAMA CARDIOLOGY, 2016, 1 (01) :63-64
[8]   Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US The Get With The Guidelines-Heart Failure Registry [J].
Pierce, Jacob B. ;
Vaduganathan, Muthiah ;
Fonarow, Gregg C. ;
Ikeaba, Uchechukwu ;
Chiswell, Karen ;
Butler, Javed ;
DeVore, Adam D. ;
Heidenreich, Paul A. ;
Huang, Joanna C. ;
Kittleson, Michelle M. ;
Joynt Maddox, Karen E. ;
Linganathan, Karthik K. ;
McDermott, James J. ;
Owens, Anjali Tiku ;
Peterson, Pamela N. ;
Solomon, Scott D. ;
Vardeny, Orly ;
Yancy, Clyde W. ;
Greene, Stephen J. .
JAMA CARDIOLOGY, 2023, 8 (07) :652-661
[9]   Heart Failure Drug Treatment- Inertia, Titration, and Discontinuation [J].
Savarese, Gianluigi ;
Kishi, Takuya ;
Vardeny, Orly ;
Eryd, Samuel Adamsson ;
Bodegard, Johan ;
Lund, Lars H. ;
Thuresson, Marcus ;
Bozkurt, Biykem .
JACC-HEART FAILURE, 2023, 11 (01) :1-14
[10]   Bridging gaps and optimizing implementation of guideline-directed medical therapy for heart failure [J].
Shahid, Izza ;
Khan, Muhammad Shahzeb ;
Fonarow, Gregg C. ;
Butler, Javed ;
Greene, Stephen J. .
PROGRESS IN CARDIOVASCULAR DISEASES, 2024, 82 :61-69